Showing results (41-50 of 57) with videos related to
Sort By:
Pageof 6
European Journal of Pharmacology|September 13, 2005
The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitroJohanna E Olijslagers, Benny Perlstein, Taco R Werkman, et al.European Journal of Pharmacology|August 28, 2014
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned ratsMaria Papathanou, Peter Jenner, Mahmoud Iravani, et al.Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Rob M A de Bie, Tom H Johnston, et al.European Journal of Pharmacology|December 14, 2004
Quetiapine increases the firing rate of rat substantia nigra and ventral tegmental area dopamine neurons in vitroTaco R Werkman, Johanna E Olijslagers, Benny Perlstein, et al.Neuropharmacology|April 5, 2025
Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autismSally Loomis, Diogo G Silva, Ranjev Savopoulos, et al.Journal of Thrombosis and Haemostasis : JTH|March 2, 2023
A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasmaViola J F Strijbis, Lorenzo G R Romano, Ka Lei Cheung, et al.Synapse (New York, N.Y.)|September 27, 2006
In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonistJeffrey C Glennon, Guus Van Scharrenburg, Eric Ronken, et al.Bioorganic & Medicinal Chemistry Letters|September 6, 2005
Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicityJos H M Lange, Herman H van Stuivenberg, Willem Veerman, et al.Bioorganic & Medicinal Chemistry Letters|February 5, 2003
SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibitionRolf van Hes, Pieter Smid, Cees N J Stroomer, et al.Bioorganic & Medicinal Chemistry Letters|November 18, 2005
Piperazinyl oxime ethers as NK-1 receptor antagonistsAdri van den Hoogenband, Jan H van Maarseveen, Andrew C McCreary, et al.Pageof 6